{
    "nctId": "NCT02419742",
    "briefTitle": "Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen",
    "officialTitle": "An Indian Multicentric Open Label Prospective Phase IV Study to Evaluate Safety and Efficacy of Trastuzumab in Her2 Positive, Node Positive or High Risk Node Negative Breast Cancer as Part of a Treatment Regimen Consisting of Doxorubicin, Cyclophosphamide, With Either Docetaxel or Paclitaxel (AC-TH) or Docetaxel and Carboplatin (TCH)",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 110,
    "primaryOutcomeMeasure": "Clinically Significant Changes in Cardiac Function As Determined by Left Ventricular Ejection Fraction (LVEF) Measurements Using Echocardiography",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed early invasive HER2 positive, node positive or high risk node negative breast cancer with no evidence of residual, locally recurrent or metastatic disease and defined as clinical stage I to IIIA that is eligible for adjuvant treatment with trastuzumab\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2\n* HER2 over expression/amplification defined as either Immunohistochemistry (IHC)3+, or IHC2+ and Fluorescence in situ Hybridization (FISH) positive as determined in a central laboratory\n* At time of starting trastuzumab therapy, LVEF measured by echocardiography\n* Screening LVEF greater than or equal to (\\>/=) 55 percent (%)\n* Adequate bone marrow, renal, and hepatic function\n* Agreement to use an adequate, non-hormonal means of contraception by women of childbearing potential\n\nExclusion Criteria:\n\n* Any contraindication to trastuzumab\n* Previous adjuvant breast cancer treatment with an approved or investigational anti-HER2 agent\n* History of other malignancy, except for curatively treated carcinoma in situ of the cervix or basal cell carcinoma and participants with other curatively treated malignancies who have been disease-free for at least 5 years\n* Past history of ductal carcinoma in situ and/or lobular carcinoma that has been treated with any systemic therapy or with radiation therapy to the ipsilateral breast where the invasive cancer subsequently develops\n* Locally advanced (Stage IIIB and IIIC) and metastatic disease (Stage IV)\n* Clinically relevant cardiovascular disorder or disease\n* Uncontrolled hypertension, or history of hypertensive crisis or hypertensive encephalopathy\n* History of severe allergic or immunological reactions, example difficult to control asthma\n* Pregnant or lactating women",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}